SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing investor attention following a series of strategic partnership expansions with U.S. national laboratories and the announcement of an upcoming Analyst Day at the NYSE. Community sentiment remains focused on the company's neutral-atom technology and perceived valuation gap relative to other quantum players, with many investors actively debating the stock's long-term potential as a defense and infrastructure play.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense market volatility and community scrutiny as investors react to a jury finding the CEO liable for defrauding shareholders during a past takeover, alongside concerns regarding softening EV demand and aggressive infrastructure spending. Community sentiment is deeply polarized, with active debates centered on the company's long-term pivot to AI and robotics versus mounting regulatory challenges and the financial implications of the current geopolitical climate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community debate the stock's volatility alongside the President's recent high-stakes ultimatum regarding Iranian power infrastructure. Sentiment remains deeply polarized, with active discussions centering on the company's financial health, the impact of escalating geopolitical tensions on energy markets, and the broader political controversy surrounding the administration's policy decisions.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors react to strong earnings results, including 18 consecutive beat-and-raise quarters and a strategic shift to GAAP profitability. The community is actively debating the stock's valuation, contrasting its robust growth and AI-driven martech platform against broader software sector volatility and lingering short interest.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV) is gaining momentum as traders highlight its technical strength, recent consolidation, and the anticipation of treasury buybacks. The community is actively discussing its potential for a breakout, bolstered by strategic partnerships and its role in building derivatives infrastructure on Ethereum.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors pivot toward the company as a key beneficiary of the enterprise AI infrastructure build-out, especially following significant volatility and regulatory scrutiny surrounding its competitor, Supermicro. Community sentiment is largely focused on the company's robust AI server backlog and expectations that it will capture substantial market share, with many participants viewing it as a safer, more stable play for capturing long-term value in the sector.

Polygon

Polygon is currently trending as investors debate the potential rebrand back to the MATIC ticker while analyzing its pivot toward regulated stablecoin payments and institutional adoption. Community sentiment remains polarized, with many users expressing frustration over recent price performance while others highlight significant network activity and the deflationary impact of token burns.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest record quarterly bookings and an upbeat 2026 outlook, fueled by relentless demand for EUV lithography machines essential to the global AI hardware arms race. While the community is actively debating the stock's premium valuation and potential for a share split, sentiment remains anchored by the company's unassailable monopoly and long-term role as the backbone of the semiconductor supply chain.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401JK community is driving momentum through a grassroots campaign that uses memes and "IRL raids" to mock traditional retirement systems, positioning the token as a rebellious alternative to a perceived broken financial model. Supporters are actively engaging on social platforms to highlight the project's educational resources and staking mechanisms, maintaining high conviction that their movement offers a viable path to financial independence.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is trending significantly higher following a blockbuster partnership with the U.S. government and Brookfield Asset Management to invest $80 billion in deploying Westinghouse nuclear reactors. Investors are cheering the move as a major validation of nuclear energy's role in powering AI and data center infrastructure, leading to heavy call-buying volume and renewed optimism for the sector's long-term capacity buildout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul class="summary-bullets"><li>While the patent was granted in September 2025, it had to pass a 6-month opposition period.</li><li>The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer.</li><li>AIM is seeking an orphan drug designation in Japan for its treatment.</li></ul>Shares of AIM ImmunoTech Inc (AIM) gave up some of its pre-market gains and was up more than 60% on Wednesday, after the company said that a Japanese patent using its proprietary Ampligen in combination with checkpoint inhibitors to treat cancer was fully approved in the country.While the patent was granted in September 2025, it had to pass a 6-month opposition period, AIM said. The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer. The company holds similar patents in the U.S. and the Netherlands.AIM, which already holds orphan drug designations for pancreatic cancer in the U.S. and Europe, also plans to seek a similar designation in Japan.<h2 class="st-heading-2">DURIPANC Study Update</h2>Earlier this month, AIM ImmunoTech partnered with Thermo Fisher Scientific’s PPD clinical research unit to design a planned Phase 3 trial of Ampligen for late-stage pancreatic cancer.&nbsp;The company also highlighted encouraging results from its ongoing DURIPANC study, including improvements in progression-free and overall survival. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center."Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer," said CEO Thomas K. Equels."AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/AIMS_jpg_04ac5ff737.webp" alt="AIMS.jpg">One user said the RSI has cooled and its time for the next leg of the rally.<stembedurl>https://stocktwits.com/Chessdoc/message/647888049</stembedurl>Year-to-date, the stock has climbed 1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

Equity

Are Medical Stocks Lagging  AIM ImmunoTech (AIM) This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.

Bet On 5 Top-Ranked Stocks With Rising P/E 

Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.

All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy

AIM ImmunoTech (AIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

This account has been verified as an official AIM representative.

Verified Account

AIM Immunotech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

AIM
AIM ImmunoTech

Feed

News

Sentiment

Fundamentals

Info

Latest AIM News

AIMAIM ImmunoTech